| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11883-010-0123-6 |
| P698 | PubMed publication ID | 20623344 |
| P50 | author | Jean Davignon | Q3171589 |
| Nabil Seidah | Q3334710 | ||
| P2093 | author name string | Geneviève Dubuc | |
| P2860 | cites work | A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo | Q21136366 |
| The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications | Q24299848 | ||
| Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels | Q24313575 | ||
| Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype | Q24563948 | ||
| Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates | Q24646644 | ||
| Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine | Q24652495 | ||
| Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes | Q24683425 | ||
| A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates | Q27655476 | ||
| Mutations in PCSK9 cause autosomal dominant hypercholesterolemia | Q28202519 | ||
| Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 | Q28588292 | ||
| Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice | Q28588849 | ||
| Sequence variations in PCSK9, low LDL, and protection against coronary heart disease | Q29616310 | ||
| The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women | Q33252167 | ||
| Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke | Q33302900 | ||
| Identification of mRNA binding proteins that regulate the stability of LDL receptor mRNA through AU-rich elements | Q33399670 | ||
| Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels | Q33577851 | ||
| Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study | Q33605219 | ||
| Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population | Q33848024 | ||
| A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis | Q34021096 | ||
| Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice | Q34219528 | ||
| A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree | Q34290323 | ||
| Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia | Q34324688 | ||
| A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. | Q34399014 | ||
| Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response | Q34459481 | ||
| Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine | Q34560107 | ||
| Genetic and metabolic determinants of plasma PCSK9 levels | Q34974626 | ||
| Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote | Q35015811 | ||
| Plasma PCSK9 levels are significantly modified by statins and fibrates in humans | Q36728777 | ||
| The proprotein convertases are potential targets in the treatment of dyslipidemia | Q36757387 | ||
| Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease | Q37024417 | ||
| Annexinopathies. | Q37056407 | ||
| A new method for measurement of total plasma PCSK9: clinical applications | Q37463260 | ||
| Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. | Q38336252 | ||
| Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. | Q39988341 | ||
| Berberine decreases PCSK9 expression in HepG2 cells | Q40000150 | ||
| Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. | Q40017196 | ||
| Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route | Q42660727 | ||
| Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. | Q43071452 | ||
| Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort | Q43209469 | ||
| Biomedicine. Lowering LDL--not only how low, but how long? | Q44265890 | ||
| Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. | Q45924780 | ||
| Commentary PCSK9 variants: A new database | Q46105944 | ||
| The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan. | Q46134367 | ||
| Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration | Q46205589 | ||
| The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population | Q46874145 | ||
| Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. | Q46885971 | ||
| Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy | Q46902329 | ||
| Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study). | Q46943734 | ||
| PCSK9 as a therapeutic target of dyslipidemia | Q57268596 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lipoprotein | Q28350 |
| atherosclerosis | Q12252367 | ||
| LDL cholesterol | Q75298271 | ||
| P304 | page(s) | 308-315 | |
| P577 | publication date | 2010-09-01 | |
| P1433 | published in | Current Atherosclerosis Reports | Q20821076 |
| P1476 | title | The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis | |
| P478 | volume | 12 |
| Q34568486 | A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor |
| Q37967197 | Annexins as organizers of cholesterol- and sphingomyelin-enriched membrane microdomains in Niemann-Pick type C disease |
| Q42505455 | Epigallocatechin gallate induces an up-regulation of LDL receptor accompanied by a reduction of PCSK9 via the annexin A2-independent pathway in HepG2 cells |
| Q34880292 | Evolving targets for lipid-modifying therapy |
| Q38723704 | Experimental Biology for the Identification of Causal Pathways in Atherosclerosis |
| Q50003529 | Genetic and microbiome influence on lipid metabolism and dyslipidemia. |
| Q57295416 | Haplosaurus computes protein haplotypes for use in precision drug design |
| Q33792840 | Low density lipoprotein receptor class A repeats are O-glycosylated in linker regions |
| Q38938935 | Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk |
| Q48345564 | My road to Damascus: how I converted to the prohormone theory and the proprotein convertases. |
| Q36320196 | New insights of altered lipid profile in Fragile X Syndrome |
| Q37981645 | On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications |
| Q38075818 | PCSK9 Inhibitors: potential in cardiovascular therapeutics |
| Q39427680 | PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. |
| Q39176815 | PCSK9 inhibitors: A new era of lipid lowering therapy. |
| Q35036348 | PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke |
| Q47303571 | Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia |
| Q35494775 | Premature coronary artery disease and familial hypercholesterolemia: need for early diagnosis and cascade screening in the Indian population |
| Q38221015 | Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy? |
| Q41851719 | The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway |
| Q36292659 | The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis |
| Q38017196 | The biology and therapeutic targeting of the proprotein convertases |
| Q35628302 | The causal exposure model of vascular disease |
| Q37880856 | The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications |
Search more.